2. Search Result
Search Result
Results for "

RDCs

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132989
    Mal-Deferoxamine

    		Reactive Oxygen Species Apoptosis Autophagy HIF/HIF Prolyl-Hydroxylase Akt Radionuclide-Drug Conjugates (RDCs) Cancer
    Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. .
    Mal-Deferoxamine
  • HY-159768A
    DOTAGA.Glu.(FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTAGA.Glu.(FAPi)2
  • HY-159767A
    (S)-DOTAGA.(SA.FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    (S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .
    (S)-DOTAGA.(SA.FAPi)2
  • HY-159770A
    (S)-EB-FAPI-B2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .
    (S)-EB-FAPI-B2
  • HY-164589
    NOPO

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NOPO
  • HY-164653
    DOTAEt

    		Others Cancer
    DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTAEt
  • HY-164590
    BCN-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    BCN-NODAGA
  • HY-164599
    TA-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA
  • HY-P10730
    DOTA-Lanreotide

    		Others Cancer
    DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-Lanreotide
  • HY-P10731
    DOTA-NAPamide

    		Others Cancer
    DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-NAPamide
  • HY-164592
    DTPA-tetra(tBu)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA-tetra(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DTPA-tetra(tBu)ester
  • HY-164594
    TA-DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA-GA
  • HY-P10732
    DOTA-cyclo(RGDfK)

    		Others Cancer
    DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-cyclo(RGDfK)
  • HY-W999782
    Propargyl-DOTA-tris(tBu)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Propargyl-DOTA-tris(tBu)ester
  • HY-P10729
    DOTA-Bombesin (1-14)

    		Others Cancer
    DOTA-Bombesin (1-14) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-Bombesin (1-14)
  • HY-164603
    3p-C-NOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NOTA
  • HY-164604
    3p-C-DEPA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-DEPA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-DEPA
  • HY-164606
    3p-C-NETA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NETA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NETA
  • HY-164596
    THP(Bz3)-Glu

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz3)-Glu
  • HY-164654
    DOTA-PEG10-azide

    		Others Cancer
    DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-PEG10-azide
  • HY-W999766
    Propargyl-NOTA(tBu)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    Propargyl-NOTA(tBu)2
  • HY-W586475
    Fluorescein-triazole-PEG5-DOTA

    		Others Cancer
    Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Fluorescein-triazole-PEG5-DOTA
  • HY-164591
    THP(Bz)3-NH2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz)3-NH2 is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz)3-NH2
  • HY-164601
    3p-C-DE4TA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-DE4TA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-DE4TA
  • HY-164602
    3p-C-NE3TA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NE3TA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NE3TA
  • HY-164593
    NH-CH2-CH2-DOTAM

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NH-CH2-CH2-DOTAM
  • HY-164656
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE

    		Drug-Linker Conjugates for ADC Cancer
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE
  • HY-164588
    NH2-PEG4-NODA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-NODA-GA
  • HY-W873634
    TRAP

    TRAP-Pr

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
    TRAP
  • HY-W011118
    DTPA anhydride

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DTPA anhydride
  • HY-W087028
    NOTA-NHS ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NOTA-NHS ester is a molecule related to radiolabeling drugs (RDC) that can be used for fluorescent labeling and radioactive nuclide labeling applications .
    NOTA-NHS ester
  • HY-164574
    BCN-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.
    BCN-DOTA
  • HY-W755033
    NH2-PEG4-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-DOTA is a bifunctional, DOTA-type metal chelator. NH2-PEG4-DOTA can be conjugated with Dextran for quantitative analysis in the presence of a highly luminescent complex. NH2-PEG4-DOTA can also bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-DOTA
  • HY-164577
    BCN-DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-DOTA-GA is a cyclooctyne-linked DOTA chelator that can be labeled with radioactive zirconium-89 and used as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells or tissues.
    BCN-DOTA-GA
  • HY-164569
    NH2 DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions. For example, NH2 DOTA-GA complexes Gd(III) ions.
    NH2 DOTA-GA
  • HY-W738256
    Maleimide-DTPA

    MDTPA

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Maleimide-DTPA (MDTPA) is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA is a good material for medical imaging or treatment.
    Maleimide-DTPA
  • HY-164575
    NH2-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NH2-NODAGA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA can react with diethyl squarate in 0.5M phosphate buffer (room temperature, 2 h, pH 7-7.5) to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride
  • HY-W241345
    DOTA-bis(tert-butyl)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-bis(tert-butyl)ester is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide conjugates (RDCs). DOTA-bis(tert-butyl)ester can be conjugated with different salts to form different metal chelators, such as (HY-B1244) hydrochloride to obtain DOTA-MN2. DOTA-MN2 can be reacted with [67]Ga-citrate to obtain radiolabeling. When (67)Ga-DOTA-MN2 is incubated in phosphate buffer solution or mouse plasma for 24 hours, it does not undergo significant decomposition. In the biodistribution experiment of NFSa tumor mice, it has high tumor uptake and rapid plasma clearance, and is a good material for SPECT and PET studies.
    DOTA-bis(tert-butyl)ester

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: